Introduction: Sucroferric oxyhydroxide (SOH) is an iron-based phosphate binder (PB), and its use has been widely expanded since its initial approval in 2014. Based on the existing data, however, it remains yet unclear whether its long-term administration is followed by iron overload in dialysis patients. The purpose of this observational study was to evaluate the longstanding effects of SOH on the anemia and iron indices in patients on dialysis.
Methods: A total of 110 patients from 3 dialysis centers were included in the study; 49 were under chronic treatment with SOH (cohort A), while 61 were either receiving other PB or no treatment for hyperphosphatemia (cohort B). We initially compared the hematologic profile of patients in 2 cohorts (phase I), and subsequently, we evaluated modifications of the above parameters in the SOH treated patients over a period of 6 months (phase II).
Results: There were no statistically significant differences between 2 cohorts in terms of hemoglobin (Hb; 11.4 ± 1.3 vs. 11.6 ± 0.9 g/dL, p = 0.375), ferritin (473 ± 230 vs. 436 ± 235 ng/mL, p = 0.419) and transferrin saturation (TSAT;26.6 ± 13.2 vs. 26.5 ± 10.6%, p = 0.675), serum phosphate concentration (4.57 ± 1.05 vs. 4.3 ± 0.96 mg/dL, p = ns), and intact PTH (286 ± 313 vs. 239 ± 296 pg/mL, p = ns). Marginally, but significantly higher calcium levels were found in cohort A compared to cohort B (9.18 ± 0.58 vs. 8.9 ± 0.51 mg/dL, respectively, p = 0.008). In phase II, no significant changes were observed in hematological parameters after a 6-month treatment with SOH (Hb: from 11.5 ± 1.1 to 11.4 ± 1.3 g/dL, p = 0.4, serum ferritin levels: from 475 ± 264 to 473 ± 230 ng/mL, p = 0.951, TSAT: from 26.5 ± 16.7 to 26.6 ± 13.2%, p = 0.933). There were also no significant changes in the administration of iron supplements or erythropoietin dose during this period.
Conclusions: SOH is an effective PB, and its long-term use is not complicated by iron overload.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000505432 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In Vitro Study on Combined Effect of Drugs for Hyperphosphatemia on Phosphorus Adsorption Capacity.
Chem Pharm Bull (Tokyo)
October 2024
Laboratory of Public Health, Faculty of Pharmacy, Kindai University.
Article Synopsis
- Phosphorus binders can be combined for better effects, but their performance might change due to pH levels or other medications.
- A study assessed how well different phosphorus binders work together, specifically looking at precipitated calcium carbonate (CC), ferric citrate hydrate (FC), lanthanum carbonate hydrate (LC), and sucroferric oxyhydroxide (SO).
- Results showed that SO maintained a strong adsorption capacity even when mixed with other binders, while combinations of CC + FC and FC + LC had decreased effectiveness due to citrate ions interfering with calcium and lanthanum ions.*
Efficacy and safety of sucroferric oxyhydroxide versus sevelamer carbonate: A systematic review and meta-analysis.
Hemodial Int
October 2024
Department of Nephrology, University Hospital of Ioannina, Ioannina, Greece.
Article Synopsis
- Phosphate binders like sucroferric oxyhydroxide and sevelamer carbonate are used in kidney replacement therapy (KRT) to lower serum phosphorus levels, which are linked to health issues in chronic kidney disease.
- This study compared the effectiveness and safety of these two drugs through a meta-analysis of five randomized trials, finding no significant difference in reducing serum phosphorus between them.
- However, sucroferric oxyhydroxide had a better gastrointestinal side effect profile, making it a preferable option for patients in KRT.
The Use of Sucroferric Oxyhydroxide Prior to Sigmoidoscopy in Patients With End-Stage Kidney Disease: A Case Report.
Can J Kidney Health Dis
September 2024
Department of Nephrology, The Ottawa Hospital, ON, Canada.
Article Synopsis
- - The text discusses a case involving a 51-year-old male with end-stage kidney disease who experienced issues during a colonoscopy due to the effects of the iron-based medication sucroferric oxyhydroxide, which is used to manage high phosphate levels in patients on dialysis.
- - During a flexible sigmoidoscopy, the medication caused the bowel to be obscured by "charcoal-like" material, making it difficult for doctors to see and evaluate the patient's condition, leading to the decision to halt the medication for two weeks before a repeat procedure.
- - After stopping the medication, the patient's repeat sigmoidoscopy was successful in providing clear visualization, ultimately revealing a benign lipoma, highlighting the importance of considering medication effects on
Management of serum phosphorus over a 1-year follow-up in patients on peritoneal dialysis prescribed sucroferric oxyhydroxide as part of routine care: a retrospective analysis.
BMC Nephrol
June 2024
Fresenius Medical Care, Global Medical Office, Waltham, MA, USA.
Article Synopsis
- This study explores the use of sucroferric oxyhydroxide (SO) for managing high serum phosphorus levels in patients with end-stage kidney disease (ESKD) undergoing peritoneal dialysis (PD).* -
- An analysis of 402 patients showed significant improvements, with the proportion of patients achieving optimal phosphorus levels rising from 32.1% at the start to between 46.5% and 54% over the year, alongside a reduction in the number of phosphate binder pills taken daily.* -
- Overall, SO treatment effectively lowered serum phosphorus levels and decreased pill burden regardless of kidney function changes, suggesting it can be a beneficial option for managing hyperphosphatemia in ESKD patients on PD
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!